Chong Kun Dang Pharmaceutical Asset Resilience Ratio
Chong Kun Dang Pharmaceutical asset resilience ratio. Chong Kun Dang Pharmaceutical (185750) has an Asset Resilience Ratio of 6.04% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Chong Kun Dang Pharmaceutical liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Chong Kun Dang Pharmaceutical (2019–2025)
Asset resilience ratio of Chong Kun Dang Pharmaceutical from 2019 to 2025. This chart shows how Chong Kun Dang Pharmaceutical's Asset Resilience Ratio has changed over time. Read total liabilities of Chong Kun Dang Pharmaceutical for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Chong Kun Dang Pharmaceutical's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Chong Kun Dang Pharmaceutical assets under control.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩110.67 Billion | 6.04% |
| Total Liquid Assets | ₩110.67 Billion | 6.04% |
Asset Resilience Insights
- Limited Liquidity: Chong Kun Dang Pharmaceutical maintains only 6.04% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Chong Kun Dang Pharmaceutical Industry Peers by Asset Resilience Ratio
Compare Chong Kun Dang Pharmaceutical's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Viatris Inc
NASDAQ:VTRS |
Drug Manufacturers - Specialty & Generic | 1.48% |
|
Tianjin Zhongxin Pharmaceutical Group Corp Ltd
SHG:600329 |
Drug Manufacturers - Specialty & Generic | 5.92% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Curaleaf Holdings Inc.
TO:CURA |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026 |
Drug Manufacturers - Specialty & Generic | -0.89% |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550 |
Drug Manufacturers - Specialty & Generic | 18.70% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Harbin Gloria Pharmaceuticals
SHE:002437 |
Drug Manufacturers - Specialty & Generic | 9.04% |
Chong Kun Dang Pharmaceutical Asset Resilience Ratio by Year (2019–2025)
Chong Kun Dang Pharmaceutical asset resilience ratio by year from 2019 to 2025. The table below shows the annual Asset Resilience Ratio data for Chong Kun Dang Pharmaceutical.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 7.24% | ₩130.27 Billion ≈ $88.28 Million |
₩1.80 Trillion ≈ $1.22 Billion |
+2.18pp |
| 2024-12-31 | 5.05% | ₩73.70 Billion ≈ $49.95 Million |
₩1.46 Trillion ≈ $988.58 Million |
-5.32pp |
| 2023-12-31 | 10.37% | ₩145.42 Billion ≈ $98.55 Million |
₩1.40 Trillion ≈ $950.41 Million |
+6.95pp |
| 2022-12-31 | 3.42% | ₩38.44 Billion ≈ $26.05 Million |
₩1.12 Trillion ≈ $762.32 Million |
-1.89pp |
| 2021-12-31 | 5.30% | ₩55.52 Billion ≈ $37.63 Million |
₩1.05 Trillion ≈ $709.33 Million |
+1.27pp |
| 2020-12-31 | 4.04% | ₩38.20 Billion ≈ $25.89 Million |
₩946.33 Billion ≈ $641.32 Million |
+2.11pp |
| 2019-12-31 | 1.93% | ₩15.45 Billion ≈ $10.47 Million |
₩801.35 Billion ≈ $543.06 Million |
-- |
About Chong Kun Dang Pharmaceutical
Chong Kun Dang Pharmaceutical Corp. manufactures, markets, and sells medicines in South Korea and internationally. It offers prescription drugs for anti-hypertension, anti-hyperlipidaemia, and anti-diabetics, as well as immunosuppressants; over-the-counter medicines; and consumer health products, such as insecticides and hair dye products, as well as health supplements. The company was founded in… Read more